Combined oral contraceptives: the optimal range of examination. Part 2
Journal Title: Міжнародний ендокринологічний журнал - Year 2018, Vol 14, Issue 7
Abstract
Combined oral contraceptives are effective drugs for contraception and treatment of reproductive disorders in polycystic ovarian syndrome. The article considers the main laboratory algorithms for excluding the most common endocrine diseases, the clinical manifestations of which are similar to those in polycystic ovarian syndrome and whose exclusion is necessary to diagnose this syndrome.
Authors and Affiliations
O. V. Rykova
Keywords
Related Articles
- EP ID EP432678
- DOI 10.22141/2224-0721.14.7.2018.149770
- Views 99
- Downloads 0
Experience of Using Pentosan Polysulfate SP 54 in Patients with Diabetic Foot Syndrome
Diabetic foot — a complex of anatomical and functional changes in the feet caused by diabetic neuropathy leading to osteoarthropathy and angiopathy, against which purulent necrotic processes may develop. Microangiopathy...
Glycated Hemoglobin in the Practice of Endocrinologist (Literature Review and Our Own Data)
This article deals with one of the most important factors in the diagnosis of diabetes mellitus — glycated hemoglobin (HbA1c). There are given the factors that may affect its value. It is noted that in recent years the w...
Blood Fibrinolytic Activity in Patients with Type 2 Diabetes Mellitus Associated with Hypothyroidism
The objective of the research was to study the level of plasminogen activator inhibitor type 1 (PAI-1) in the blood serum of patients with type 2 diabetes mellitus (DM) in combination with hypothyroidism. We have observe...
Features of the Clinical Course of Adrenal Incidentalomas
The objective of the study was to examine the clinical features of adrenal incidentalomas. 98 clinical observations of patients with adrenal incidentalomas receiving in- and out-patient treatment in the clinic of Republi...
Efficiency and Safety of Metformine and Pioglitazone in Patients with Coronary Heart Disease and Diabetes Mellitus Type 2
A combination of metformin (MF) (2 g daily) and pioglitazone (PG) (30 mg daily) in 57 patients with coronary heart disease (CHD) and diabetes mellitus type 2 (DM 2) reduces the indicators of low grade chronic inflammatio...